Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd. develops orally delivered peptide and protein replacement therapies as a clinical-stage biopharmaceutical company. News about ENTX centers on its N-Tab® oral peptide platform and pipeline candidates, including EB613, an oral PTH(1-34) tablet for osteoporosis, and EB612, a long-acting oral PTH peptide replacement tablet for hypoparathyroidism.
Recurring updates also cover FDA communications and clinical-development plans, OPKO collaboration activity, financial results, private placements and warrant-linked capital actions, board and governance changes, and medical-community discussions around osteoporosis and oral anabolic therapy.
Entera (NASDAQ: ENTX) announced that CEO Miranda Toledano will present at three fall 2026 investor conferences: the Cantor Global Healthcare Conference on September 10 in New York, the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 9 in Boston, and the Evercore ISI 9th Annual Healthcare Conference from November 30–December 2 in Miami.
Entera is a clinical-stage company developing oral peptide and protein replacement therapies using its N-Tab® platform, with lead candidate EB613 for osteoporosis and additional programs in hypoparathyroidism, obesity, metabolic syndromes, and rare malabsorption conditions.
Entera Bio (NASDAQ: ENTX) appointed Riccardo Paolo Camisasca, M.D., as Chief Medical Officer, adding more than 30 years of global pharmaceutical R&D, clinical development and medical affairs experience from roles at Sumitomo Pharma, Takeda, Novartis and others. The hire strengthens Entera’s clinical leadership ahead of the planned Phase 3 program for EB613.
EB613, an oral once-daily PTH(1-34) tablet for osteoporosis, previously completed a 6‑month, 161‑patient placebo‑controlled Phase 2 study that met all biomarker and bone mineral density endpoints without significant safety concerns. According to Entera, EB613 showed rapid bone formation marker increases, BMD gains at multiple skeletal sites and 3D‑DXA improvements consistent with published subcutaneous teriparatide data.
Entera is also advancing EB612 for hypoparathyroidism, an oral oxyntomodulin for obesity and metabolic syndromes, and an oral GLP‑2 tablet for rare malabsorption conditions in collaboration with OPKO Health.
Entera (NASDAQ: ENTX) reported second quarter 2026 results and significant pipeline and financing milestones. The FDA accepted the company’s plan for a single 12‑month, ~750‑patient, randomized Phase 3 registrational trial of oral anabolic tablet EB613 in postmenopausal osteoporosis, supporting a potential 505(b)(2) NDA with a scientific bridge to Forteo. Phase 3 initiation is planned for late 2026, with topline data expected in 2H 2028.
Preclinical data for EB612 in hypoparathyroidism and non‑human primate data for EB618 in obesity were presented at ENDO 2026. Post‑quarter, Entera closed an oversubscribed $275 million private placement led by BVF, expected to fund EB613 through NDA submission and extend cash runway into 2030. Q2 2026 net loss was $7.3 million with no revenues.
Entera Bio (NASDAQ: ENTX) announced that post-hoc data from its Phase 2 trial of EB613, an oral PTH(1-34) tablet being developed as the first oral anabolic osteoporosis treatment, has been selected for a Plenary Poster Presentation and a second poster at the ASBMR 2026 Annual Meeting in Boston, October 9–12, 2026.
The sensitivity analysis evaluates EB613’s anabolic effects on bone mineral density and bone turnover markers at 6 months in postmenopausal women with osteoporosis at high fracture risk. According to Entera, the 161-patient, 6‑month, placebo-controlled Phase 2 study met biomarker and BMD endpoints without significant safety concerns, showing dose‑proportional increases in bone formation markers and increases in lumbar spine, total hip, and femoral neck BMD. Entera plans a single randomized, double‑blind, placebo‑controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis to support a potential NDA submission for EB613.
Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will participate in a fireside chat and 1x1 meetings at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026 at 1:00 p.m. Eastern Time at the InterContinental Boston Hotel, with the overall event taking place in person from August 11–13, 2026.
A live webcast and presentation slides will be accessible via the provided link, with a replay available for 365 days. Entera is a clinical-stage company developing oral peptide and protein replacement therapies, including lead osteoporosis candidate EB613, which met primary and secondary endpoints in a Phase 2 study.
Entera Bio (NASDAQ: ENTX) completed an oversubscribed $275 million private placement (PIPE), for which Greenberg Traurig advised the company. According to Entera Bio, the financing is expected to extend its cash runway into 2030 and fully support Phase 3 registrational studies of EB613, an oral PTH (1-34) tablet in development for osteoporosis.
According to data compiled by Arx Capital Markets, this is the largest publicly disclosed Israeli biotech PIPE on record and the ninth largest Israeli PIPE overall. The Greenberg Traurig deal team was led from Miami with support from the firm’s Tel Aviv office.
Entera Bio (NASDAQ: ENTX) entered a securities purchase agreement for an oversubscribed $275 million private placement, led by existing investor BVF Partners. The company will issue 122,961,215 ordinary shares and pre-funded warrants to purchase up to 11,842,695 ordinary shares at a purchase price of $2.04 per share or warrant (less the minimal exercise price per share for the warrants). The pre-funded warrants are immediately exercisable, have no expiration, and include beneficial ownership caps, with customary adjustments.
The placement, priced at-the-market under Nasdaq rules, is expected to close on or about July 28, 2026, subject to customary conditions. Upon closing, BVF will gain the right to designate two directors to Entera’s board, subject to standard eligibility requirements. According to Entera, net proceeds combined with existing cash are expected to fully fund Phase 3 registrational studies and a planned NDA submission for EB613 in osteoporosis, advance EB612 into Phase 1 for hypoparathyroidism in collaboration with OPKO Health, and support working capital and general corporate purposes. The company expects this financing to extend its cash runway into 2030.
Entera Bio (NASDAQ: ENTX) received positive FDA feedback on its registrational Phase 3 protocol for EB613, an oral anabolic tablet for postmenopausal osteoporosis. The FDA accepted a single, 750-patient, placebo-controlled trial with 12‑month total hip BMD as the primary endpoint to support a potential NDA.
The NDA package is expected to include 12‑month Phase 3 data, a 24‑month open-label extension, and a 505(b)(2) scientific bridge with Forteo. A prior Phase 2 study in 161 women met primary and secondary endpoints. Phase 3 initiation is planned for late 2026, with topline data in second-half 2028.
Entera (NASDAQ:ENTX) reported preclinical ENDO 2026 data for EB612 in hypoparathyroidism and EB618 in obesity and metabolic disorders, both co-developed with OPKO Health.
EB612 and EB618 showed sustained pharmacologic effects, robust bioavailability, favorable tolerability and support advancement toward clinical development, including a planned IND for EB612 in late 2026.
Entera Bio (NASDAQ:ENTX) presented Phase 1 data at ENDO 2026 comparing single-tablet EB613, multi-tablet EB613 and injectable Forteo in 15 healthy participants.
Single-tablet EB613 showed comparable PK/PD, calcemic effects and safety to multi-tablet EB613 and Forteo, supporting selection of the single tablet as Entera’s planned Phase 3 candidate for osteoporosis.